Too few American young adults are receiving needed statin medications, according to findings published in JAMA Cardiology.
Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia.
Oxidized low-density lipoprotein (ox-LDL) as a proxy for oxidative stress is associated with metabolic syndrome and its components.
Healthier diets may be a factor in the ongoing decline in cholesterol levels for Americans.
Women and minorities with HIV are less frequently tested for dyslipidemia, according to a new study from IDWeek 2016.
A mean 51% reduction in LDL cholesterol was seen in the group assigned to the 300 mg dose of inclisiran.
An analysis of more than 80,000 Chinese participants found that all alcohol consumption slowed the decline of HDL cholesterol in the body.
Antihypertensive drugs and rosuvastatin did not prevent or worsen cognitive decline in those at intermediate risk for CVD.
For patients with type 1 diabetes, the correlation between PCSK9 and LDL cholesterol is only seen in the highest tertile for HbA1c.
As children age, the impact of changes in HbA1c and BMI on LDL cholesterol and non-HDL cholesterol levels increases.